Hexarelin: What the Research Shows About This Potent GH Secretagogue

What it is

Hexarelin is a six-amino-acid peptide built in the early 1990s as a more stable, more potent version of GHRP-6. It works through the ghrelin receptor like the rest of its family, and in head-to-head human studies it releases more growth hormone per dose than any of them.

Two things set it apart beyond potency. It binds a second receptor found in heart muscle, which led to a line of research on the heart. And its effect fades faster than any other GHRP with daily use, which is the main reason it never became the default choice.

What it is studied for

Growth hormone release. Heart function, in growth-hormone-deficient adults. Desensitization, meaning how quickly the body stops responding. And the usual cortisol and prolactin side signals. Nothing on muscle, fat, or recovery in a trial.

What the evidence actually shows

In humans

In healthy adults, a single dose of hexarelin produced growth hormone peaks well above those from GHRP-6 or GHRP-2, making it the most potent acute growth hormone secretagogue in the class (Ghigo et al., 1994).

The desensitization is also documented in people. When hexarelin was given repeatedly to children over weeks, the growth hormone response shrank progressively, a drop that users report within four to eight weeks of daily use (Cappa et al., 1993). This is more pronounced than with other GHRPs.

The heart finding comes from a small study in adults with growth hormone deficiency, where hexarelin improved measures of how strongly the heart contracts. The sample was small, and the study could not tell whether the effect came from the growth hormone rise or from hexarelin acting on the heart directly (Bisi et al., 1999).

Cortisol and prolactin rise after a dose, more than with ipamorelin and in the same range as GHRP-2.

In animals and cells

Researchers identified a distinct receptor for GHRP-type peptides in heart tissue that appears to influence contraction strength and resistance to injury, which is the mechanism behind the cardiac interest (Bodart et al., 2002). Animal studies suggest protection against heart damage from restricted blood flow. None of this has been tested as a treatment in people.

From user reports

A strong first few weeks, with sleep, hunger, and water retention effects, then a noticeable fade. Users cycle it in short runs or rotate it with other GHRPs for that reason. None of it measured.

How it works

Hexarelin binds the ghrelin receptor and produces a large growth hormone pulse, with the same partial lifting of the somatostatin brake as its relatives. With repeated stimulation the receptor and the pituitary’s response downregulate, so each dose does less. The heart receptor is a separate site with no direct connection to growth hormone.

How it is used in studies

Human studies used single doses around 1 to 2 micrograms per kilogram. Users inject 100 to 200 micrograms under the skin one to three times a day for short cycles of two to four weeks, then stop or switch to another GHRP to let sensitivity return. See the stacks guide and the storage guide.

Side effects and unknowns

Documented: cortisol and prolactin rises, flushing, tiredness, and the desensitization itself. Reported: water retention, tingling in the hands, hunger (less than GHRP-6). The class unknowns apply, blood sugar and IGF-1 over time. Specific to hexarelin: nobody has studied what repeated strong cardiac-receptor stimulation does, and the heart data is small and old. See the safety guide.

How it compares

• GHRP-6 and GHRP-2: weaker pulses, slower desensitization.
• Ipamorelin: a smaller pulse with none of the cortisol or prolactin and no rapid fade; the usual choice for sustained use.
• MK-677: oral and all-day, with two years of human data showing the pituitary keeps responding.
• CJC-1295: GHRH-type, the stacking partner. See the muscle growth guide.

Legal status

Not approved in any country. Sold as a research chemical. WADA bans it in and out of competition.

Bottom line

Hexarelin gives the biggest growth hormone pulse in its class and keeps giving it for a few weeks, then fades. Its heart research is a genuine lead that stopped at a small study. For anyone wanting a growth hormone peptide to use for months, the desensitization makes it the wrong tool, which is why it is more discussed than used.

References

1. Ghigo E, et al. (1994). Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. J Clin Endocrinol Metab. PubMed
2. Cappa M, et al. (1993). Effect of repeated administration of hexarelin on the growth hormone releasing activity in children. Eur J Endocrinol. PubMed
3. Bodart V, et al. (2002). Identification and characterization of a new growth hormone-releasing peptide receptor in the heart. Circ Res. PubMed
4. Bisi G, et al. (1999). Cardiac effects of hexarelin in GH-deficient adults. Eur J Endocrinol. PubMed

See also

• Peptide
  GHRP-2: What the Research Shows About This Second-Generation GH Secretagogue

  GHRP-2 is a six-amino-acid peptide that copies ghrelin, the hunger hormone, to make the pituitary release a pulse of growth hormone. Japan approved it as a one-dose diagnostic test; no one has trialed it as a treatment.

• Peptide
  GHRP-6: What the Research Shows About This Growth Hormone Releasing Peptide

  GHRP-6 is the six-amino-acid peptide that led to the discovery of the ghrelin receptor. It reliably releases growth hormone in people and makes them very hungry. No trial has tested it for muscle or recovery.

• Peptide
  CJC-1295: What the Evidence Says About This GHRH Analog

  CJC-1295 is a longer-lasting version of GHRH, the signal that tells the pituitary to release growth hormone. The DAC form raised GH and IGF-1 for days in one small trial; the no-DAC form (Mod GRF 1-29) has no human trial of its own.